NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Kyndryl Holdings, Inc. (“Kyndryl” or the “Company”) (NYSE: KD).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  The class action concerns whether Kyndryl and certain of it ...

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc, alleging securities fraud and unlawful business practices by the company and certain officers and/or directors [2]. Group 1: Lawsuit Details - Investors are encouraged to contact Pomerantz LLP for participation in the class action, with a deadline to apply as Lead Plaintiff by April 6, 2026 [2]. - A copy of the Complaint related to the class action can be accessed at Pomerantz's website [2]. Group 2: Company Performance and Stock Impact - On July 9, 2025, Mereo and Ultragenyx Pharmaceutical Inc. announced that the Phase 3 Orbit study was progressing towards a final analysis, leading to a significant drop in Mereo's ADR price by $1.25, or 42.52%, closing at $1.69 on July 10, 2025 [4]. - On December 29, 2025, Mereo reported that neither the Orbit nor the Cosmic Phase 3 studies achieved statistical significance, resulting in a drastic decline in ADR price by $2.02, or 87.7%, closing at $0.29 [5].

Core Viewpoint - Medpace Holdings, Inc. is under investigation for potential violations of federal securities laws following a significant drop in its stock price despite reporting strong Q4 earnings [1][2]. Financial Performance - Medpace reported Q4 revenue of $708.5 million and GAAP EPS of $4.67, both exceeding Wall Street consensus estimates [2]. - The company's shares fell approximately 10% by mid-day and closed down 15.9%, with a trading volume of about $10.2 million during the sell-off, indicating heightened trading activity [2]. Market Reaction - The decline in stock price was attributed to a bookings shortfall, which overshadowed the positive sales and profit figures [3]. - The book-to-bill ratio missed expectations, leading to a sharp decline in stock price and raising concerns about future demand [3]. Institutional Activity - Principal Financial Group reduced its stake in Medpace by 8.4% prior to the earnings release, while Representative David Taylor purchased shares shortly before [4]. - The timing of these transactions is relevant to the ongoing investigation [4]. Analyst Commentary - Analysts questioned management about the nature of booking deterioration during the Q4 earnings call, highlighting concerns over direct-fee growth and cancellation levels [5]. - Management acknowledged that the level of cancellations was the highest compared to the previous year, describing them as "broad-based" without providing clear reasons [5].

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Richtech Robotics Inc. (“Richtech” or the “Company”) (NASDAQ: RR).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  The class action concerns whether Richtech and certain o ...

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Vistagen Therapeutics, Inc. (“Vistagen” or the “Company”) (NASDAQ: VTGN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  The class action concerns whether Vistagen and cer ...

Core Viewpoint - Hagens Berman is notifying investors about a securities class action against Klarna Group plc, focusing on alleged misstatements in the company's September 2025 IPO documents [1][4]. Group 1: Allegations and Investigation - The investigation centers on claims that Klarna's IPO documents misled investors by highlighting its credit modeling performance while failing to disclose aggressive lending practices to financially unsophisticated consumers [4][8]. - The complaint alleges that Klarna's offering documents materially understated the credit risks associated with lending to clients experiencing financial hardship [8]. - Following the IPO, Klarna reported a 102% year-over-year increase in its provision for credit losses, raising concerns about the transparency of its IPO documents [4][5][8]. Group 2: Financial Impact - Just weeks after the IPO, Klarna's stock price fell nearly 22% below the $40 IPO price due to the revelation of increased credit loss provisions [4][8]. - The significant spike in credit loss provisions indicates potential flaws in Klarna's credit modeling, which was previously presented as robust [8]. Group 3: Next Steps for Investors - Investors who purchased Klarna shares during the September 2025 IPO and incurred losses are encouraged to contact Hagens Berman for assistance [3][6]. - The lead plaintiff deadline for the class action is set for February 20, 2026 [1][7].

Did you buy KD securities between August 7, 2024, and February 9, 2026? Affected Kyndryl Holdings, Inc. Investor Summary Who: Kyndryl Holdings, Inc. (NYSE: KD)What: Securities fraud class action lawsuit filedClass Period: August 7, 2024, through February 9, 2026Deadline to Seek Lead Plaintiff Status: April 13, 2026Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company’s cash management practices and internal control over financial reporting.Investor Action: Contact Kessler T ...

Core Insights - Kessler Topaz Meltzer & Check, LLP is investigating potential violations of federal securities laws on behalf of investors of Commvault Systems, Inc. [1] - Commvault reported a 40% growth in SaaS ARR to $364 million for Q3 fiscal 2026, but this represents a deceleration from the 56% growth reported in Q2 fiscal 2026 [2] - Following the earnings report, Commvault's stock price dropped by approximately 31.1%, from $129.36 to $89.13 per share [3] Company Performance - Commvault's SaaS ARR reached $364 million, indicating significant growth [2] - The company experienced a notable deceleration in growth rate, dropping from 56% to 40% [2] Market Reaction - The stock price decline of $40.23 per share reflects investor concerns regarding the deceleration in growth [3]

Core Viewpoint - Klarna Group plc is facing a securities fraud class action lawsuit due to significant losses incurred by investors following its IPO and subsequent financial disclosures that revealed a substantial increase in credit loss provisions [1] Group 1: Company Overview - Klarna Group plc conducted its IPO on September 10, 2025, selling 34.3 million shares at $40 per share [1] - Following the IPO, the company's stock price has significantly declined, closing at $31.63 per share on November 18, 2025, after a 9.3% drop due to negative financial results [1] Group 2: Financial Performance - In its third quarter 2025 financial results, Klarna reported a 39% increase in its provision for credit losses, attributed to changes in market and product mix, particularly an increased share of the U.S. market in its Gross Merchandise Volume (GMV) [1] Group 3: Legal Proceedings - The class action lawsuit alleges that Klarna's management made materially false and misleading statements regarding the company's business and operations, particularly underestimating the risk of increased loss reserves shortly after the IPO [1] - Investors who acquired Klarna securities in connection with the IPO have until February 20, 2026, to seek appointment as lead plaintiffs in the lawsuit [1]

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Plug Power Inc. (“Plug Power” or the “Company”) (NASDAQ: PLUG) and certain officers. The class action, filed in the United States District Court for the Northern District of New York, and docketed under 26-cv-00165, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Plug Power securities between January 17, 2025 and Nove ...